| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/15/2002 | US20020111374 Estrogen receptor modulators |
| 08/15/2002 | US20020111360 Quinazoline formulations and therapeutic use thereof |
| 08/15/2002 | US20020111355 Antitumor agents; contraceptives |
| 08/15/2002 | US20020111354 Novel heteroary1 derivatives and their use as medicaments |
| 08/15/2002 | US20020111353 Antiinflammatory agents; central nervous system disorders;antidiabgetic agents; rheumatic disorders |
| 08/15/2002 | US20020111345 Use of taurolidine to treat tumors |
| 08/15/2002 | US20020111335 Bactericides, bacteriostats |
| 08/15/2002 | US20020111329 Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| 08/15/2002 | US20020111328 Anticancer, antitumor agent |
| 08/15/2002 | US20020111300 Methods for reduced renal uptake of protein conjugates |
| 08/15/2002 | US20020111294 Administering an organocobalt complex |
| 08/15/2002 | US20020110889 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/15/2002 | US20020110888 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/15/2002 | US20020110872 Cytotoxic factors for modulating cell death |
| 08/15/2002 | US20020110868 Tumor necrosis factor ptotein; for use in the treatment of rheumatic diseases and arthritis |
| 08/15/2002 | US20020110858 Lymphocytic membrane proteins |
| 08/15/2002 | US20020110853 Polypeptide; for use in the treatment of tumors |
| 08/15/2002 | US20020110841 Regulation of cell growth by MUC1 |
| 08/15/2002 | US20020110840 Detecting modulators of interferon generation; obtain cells, incubate with modulator, monitor concentration of inflammatory cytokine, amplified cytokine concentration indicates modulators |
| 08/15/2002 | US20020110836 PD-L2 molecules: novel PD-1 ligands and uses therefor |
| 08/15/2002 | US20020110832 Compositions and methods for the therapy and diagnosis of colon cancer |
| 08/15/2002 | US20020110590 Pharmaceutical formulation containing DEMO for the treatment of cancer |
| 08/15/2002 | US20020110586 Liposomal antineoplastic drugs and uses thereof |
| 08/15/2002 | US20020110566 Administering fusion protein comprising a heat shock protein (hsp) or an immunostimulatory fragment thereof, and protein of a human papilloma virus (HPV), or an antigenic fragment thereof, for therapy of wart |
| 08/15/2002 | US20020110559 Confering an immune response to a tumor cell in a mammal by administering antibody which binds to aspartyl (asparaginyl) beta hydroxylase (HAAH) |
| 08/15/2002 | US20020110538 Methods and products for tumor immunotherapy using cytokines |
| 08/15/2002 | CA2437717A1 G-protein coupled receptors |
| 08/15/2002 | CA2437571A1 Receptors and membrane-associated proteins |
| 08/15/2002 | CA2437497A1 Lipid-associated molecules |
| 08/15/2002 | CA2437437A1 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, pharmaceutical, composition adenosine a3 receptor affinitive agent, intraocular-pressure reducing agent, pharmaceutical preparation for prevention and treatment of glaucoma, and intraocular-pressure reducing method |
| 08/15/2002 | CA2437260A1 Oxazolyl-pyrazole derivatives as kinase inhibitors |
| 08/15/2002 | CA2437248A1 Jnk inhibitor |
| 08/15/2002 | CA2437185A1 Timm8b-related protein |
| 08/15/2002 | CA2437087A1 Methods for the administration of amifostine and related compounds |
| 08/15/2002 | CA2437085A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists |
| 08/15/2002 | CA2436741A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents |
| 08/15/2002 | CA2436738A1 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 08/15/2002 | CA2436735A1 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof |
| 08/15/2002 | CA2436470A1 Intracellular signaling molecules |
| 08/15/2002 | CA2435835A1 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| 08/15/2002 | CA2435586A1 Preparation of cartilage extracts using organic solvents |
| 08/15/2002 | CA2434944A1 Secreted proteins |
| 08/15/2002 | CA2434566A1 Parenteral formulation containing epothilone analogs |
| 08/15/2002 | CA2434302A1 Therapeutic and diagnostic compounds, compositions, and methods |
| 08/15/2002 | CA2433439A1 Proteins and nucleic acids encoding same |
| 08/14/2002 | EP1231262A1 Method of in vitro culture of lymphocytes and gene therapy compositions |
| 08/14/2002 | EP1230932A2 Use of antibodies for anticancer vaccination |
| 08/14/2002 | EP1230923A1 Tocotrienols as inhibitors for neovascularisation, cell multiplication, lumen formation and fgf |
| 08/14/2002 | EP1230919A2 Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage |
| 08/14/2002 | EP1230389A1 Antisense inhibition of pi3 kinase p55 gamma expression |
| 08/14/2002 | EP1230378A2 An oncolytic adenovirus |
| 08/14/2002 | EP1230375A1 Inhibiting gene expression with dsrna |
| 08/14/2002 | EP1230367A1 19 human secreted proteins |
| 08/14/2002 | EP1230364A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 08/14/2002 | EP1230360A2 15 human secreted proteins |
| 08/14/2002 | EP1230357A2 Genes differentially expressed in tr1 cells and their use in the manufacture of immunoregulatory compositions |
| 08/14/2002 | EP1230356A2 Pentraxin i and pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds |
| 08/14/2002 | EP1230349A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 08/14/2002 | EP1230346A2 Method for enhancing t cell reactivity toward tumour antigens |
| 08/14/2002 | EP1230271A1 Hedgehog fusion proteins and uses |
| 08/14/2002 | EP1230270A1 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents |
| 08/14/2002 | EP1230268A2 Heteroclitic analogs of class i epitopes |
| 08/14/2002 | EP1230264A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 08/14/2002 | EP1230259A1 S-allylmercaptoglutathione and uses thereof |
| 08/14/2002 | EP1230255A1 25 human secreted proteins |
| 08/14/2002 | EP1230254A1 Antisense modulation of src-3 expression |
| 08/14/2002 | EP1230244A2 Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same |
| 08/14/2002 | EP1230236A1 Compound with growth hormone releasing properties |
| 08/14/2002 | EP1230232A2 Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/14/2002 | EP1230227A1 Benzoxa-and benzothiazolyl sulfamates and their use as steroid sulfatase inhibitors |
| 08/14/2002 | EP1230222A1 1-benzylpyrazoles-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 08/14/2002 | EP1230215A1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 08/14/2002 | EP1230214A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 08/14/2002 | EP1229942A1 Method and formula for tumor remission and suppression of cancer |
| 08/14/2002 | EP1229941A2 Nucleic acid-containing complex |
| 08/14/2002 | EP1229938A2 Potentiation of prodrug efficacy |
| 08/14/2002 | EP1229936A2 Use of anti-idiotypical antibodies as vaccines against cancer |
| 08/14/2002 | EP1229935A1 Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| 08/14/2002 | EP1229934A2 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 08/14/2002 | EP1229933A2 Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
| 08/14/2002 | EP1229922A2 Aplidine treatment of cancers |
| 08/14/2002 | EP1229920A1 Therapy with 2-5a and interferon |
| 08/14/2002 | EP1229916A2 Combination chemotherapy |
| 08/14/2002 | EP1229910A1 Integrin receptor antagonists |
| 08/14/2002 | EP1229908A1 USE OF NSAIDs FOR THE TREATMENT OF PANCREATIC CANCER |
| 08/14/2002 | EP1229906A2 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders |
| 08/14/2002 | EP1229903A1 A method for chemoprevention of prostate cancer |
| 08/14/2002 | EP1189922A4 Steroid derivatives |
| 08/14/2002 | EP1067955B1 Use of erythropoietin in the treatment of multiple myeloma |
| 08/14/2002 | EP0954329B1 Method of killing target cells in harvested cell populations with two immunotoxins |
| 08/14/2002 | EP0906262B1 Colchicine-skeleton compounds, their use as medicaments and compositions containing them |
| 08/14/2002 | EP0814823B1 Polyphenol fractions of tea, the use thereof and formulations containing them |
| 08/14/2002 | EP0807111B1 Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same |
| 08/14/2002 | EP0806964B1 Chemical compounds |
| 08/14/2002 | EP0800399B1 Combined therapeutical treatment of hyperproliferative diseases |
| 08/14/2002 | EP0790974B1 Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors |
| 08/14/2002 | EP0672193B1 Use of oligonucleotides having a conserved g 4 core sequence for the preparation of a medicament |
| 08/14/2002 | EP0535034B1 Pharmaceutically active benzoquinazoline compounds |
| 08/14/2002 | DE10158523A1 Hemmung der Transkription eines Zielgens in einer Zelle oder in Geweben Inhibition of transcription of a target gene in a cell or in tissue |
| 08/14/2002 | DE10105989A1 Substituierte Oxazolidinone und ihre Verwendung Substituted oxazolidinones and their use |